Citation: L. Wiesmuller, The tumor suppressor p53 in the center of a strategy aiming at the alleviation of side effects in cancer therapies, ANGEW CHEM, 39(10), 2000, pp. 1768
Authors:
Susse, S
Janz, C
Janus, F
Deppert, W
Wiesmuller, L
Citation: S. Susse et al., Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53, ONCOGENE, 19(39), 2000, pp. 4500-4512
Authors:
Albrechtsen, N
Dornreiter, I
Grosse, F
Kim, E
Wiesmuller, L
Deppert, W
Citation: N. Albrechtsen et al., Maintenance of genomic integrity by p53: complementary roles for activatedand non-activated p53, ONCOGENE, 18(53), 1999, pp. 7706-7717
Authors:
Dudenhoffer, C
Kurth, M
Janus, F
Deppert, W
Wiesmuller, L
Citation: C. Dudenhoffer et al., Dissociation of the recombination control and the sequence-specific transactivation function of P53, ONCOGENE, 18(42), 1999, pp. 5773-5784
Authors:
Janus, F
Albrechtsen, N
Knippschild, U
Wiesmuller, L
Grosse, F
Deppert, W
Citation: F. Janus et al., Different regulation of the p53 core domain activities 3 '-to-5 ' exonuclease and sequence-specific DNA binding, MOL CELL B, 19(3), 1999, pp. 2155-2168